Name: Anti-Human CTLA-4 (Ipilimumab Biosimilar)
Brand: InnoCyto
SKU: 503403
Price: 2000 USD
Availability: InStock

Shop Now Contact

Anti-Human CTLA-4 (Ipilimumab Biosimilar)

InnoCyto Product Image

Cat #	Size	Price
503401	1 mg	$190
503402	5 mg	$750
503403	20 mg	$2000

Bulk/Custom

Product Details

Clone	Ipilimumab
Application	Flow cytometry, animal model study
Host Species	Mammalian cells
Reactivity	Human
Format	Liquid
Product Description	Anti-Human CTLA-4 (Ipilimumab Biosimilar)
Isotype	Human IgG1
Regulatory Status	RUO
Clonality	Recombinant
Immunogen	Human CTLA-4
Species specificity	Human
Purity	>95% by reducing SDS-PAGE
Grade	In vivo
Storage Conditions	4ºC
Maximal Shelf Life	12 months
Synonyms	CD152
Target Name	CTLA-4, CTLA4, Cytotoxic T-Lymphocyte Antigen 4
Antibody Type	Recombinant
Research Areas	Tregs, Activated T cells, Autoimmunity, Immune Checkpoints, Cancer Immunology
See All Formats	Clone Ipilimumab

Background Information

Ipilimumab is a fully human monoclonal antibody that belongs to the immunoglobulin G1 kappa (IgG1κ) subclass and is designed to target cytotoxic T-lymphocyte–associated protein 4 (CTLA-4, also known as CD152). Structurally, Ipilimumab is a recombinant glycoprotein with an approximate molecular weight of 148 kilodaltons (kDa). The molecule consists of two identical heavy chains and two identical light chains linked through disulfide bonds, forming the classical Y-shaped structure characteristic of IgG antibodies. Each heavy chain contains one variable (VH) and three constant (CH1-CH3) domains, while each light chain includes one variable (VL) and one constant (CL) domain. The molecule is expressed in mammalian systems, typically Chinese Hamster Ovary (CHO) cells, allowing proper glycosylation and folding necessary for stability and bioactivity.

The antigen-binding regions of Ipilimumab are defined by complementarity-determining regions (CDRs) within the variable domains of the heavy and light chains. These CDRs form the paratope that recognizes and binds with high affinity to an extracellular epitope on CTLA-4, an immune checkpoint receptor expressed on activated T cells. CTLA-4 normally interacts with the costimulatory ligands CD80 (B7-1) and CD86 (B7-2) present on antigen-presenting cells, transmitting an inhibitory signal that limits T-cell activation. By binding to CTLA-4, Ipilimumab sterically blocks its interaction with these ligands, thereby maintaining the availability of CD80/CD86 for engagement with CD28, the activating receptor on T cells. This molecular blockade results in the enhancement and prolongation of T-cell activation in in vitro immunological models.

The Fc (fragment crystallizable) region of Ipilimumab, derived from the human IgG1 isotype, contributes to molecular stability and extended serum persistence through interactions with the neonatal Fc receptor (FcRn). It also retains potential for limited effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement activation, in certain experimental contexts.

Frequently Asked Questions

What are InnoCyto Biosimilar products?

InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.

How similar are these biosimilars to the original therapeutic antibody?

Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.

Are these antibodies suitable for in vivo studies?

Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.

What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?

A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.

What quality and purity standards do biosimilar antibodies meet?

All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.

Which therapeutic targets and mechanisms are covered in the Biosimilar line?

The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.

Search Tips